The performance of companies tied to iconic drugs like Viagra presents a complex investment picture. While the initial surge of copyright, fueled by Viagra's remarkable popularity, generated substantial returns, the patent expiration in key territories has introduced considerable uncertainty . Investors are now grappling with the effect of rival me